A Phase 2 interventional study of Carboplatin and Docetaxel in ATM Gene Mutation, BRCA1 Gene Mutation and BRCA2 Gene Mutation, sponsored by University of Washington. Terminated at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by University of Washington · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This phase II trial studies how well docetaxel with carboplatin followed by rucaparib camsylate works in treating patients with metastatic castration resistant prostate cancer (spread outside of prostate and resistant to testosterone suppression) with homologous recombination DNA repair deficiency. Chemotherapy drugs, such as docetaxel and carboplatin, work to stop the growth of cancer cells, by stopping them from dividing or spreading. Rucaparib camsylate may stop the growth of tumor cells with defects in the ability to repair mistakes in DNA by forcing additional errors so that the cancer cells cannot overcome the number of errors and will then die. Giving induction docetaxel and carboplatin followed by maintenance rucaparib camsylate may work better in treating patients with castration resistant prostate cancer.
OUTLINE:
INDUCTION: Patients receive docetaxel intravenously (IV) and carboplatin IV on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
MAINTENANCE: Patients receive rucaparib camsylate orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up periodically.
University of Washington is the lead sponsor of 1,434 studies on the registry; 225 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 136 (86%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Presence of disease on bone or computed tomography (CT) scan
No prior is allowed except:
Documented evidence of at least ONE or MORE of the following:
* Pathogenic mutation or inactivating alteration of a gene involved in homologous recombination repair in the tumor
Note, that if this alteration is identified in a circulating tumor deoxyribonucleic acid (ctDNA) assay, the variant-allele fraction must be > 20% to indicate relevance to predominant tumor clone
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INDUCTION: Patients receive docetaxel IV and carboplatin IV on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive rucaparib camsylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: Carboplatin · Drug: Docetaxel · Other: Laboratory Biomarker Analysis · Drug: Rucaparib Camsylate · Drug: Rucaparib
Given IV
Also known as: Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo
Given IV
Also known as: Docecad, RP56976, Taxotere, Taxotere Injection Concentrate
Correlative studies
Given PO
Also known as: 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt, C0-338, Rubraca, Rucaparib Phosphate
Given PO
Also known as: 283173-50-2, 6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-
Radiographic Progression Free Survival Assessed by Assessment Using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1/Prostate Cancer Working Group 3 (PCWG3) Criteria
Radiologic progression free survival (rPFS) is defined as the time from first dose of docetaxel/carboplatin to the date of first objective evidence of radiographic progression (soft tissue or bone lesion) or death due to any cause, whichever occurs first. Radiographic disease progression includes confirmed bone disease progression and soft tissue disease progression adjudicated by investigator assessment using the RECIST 1.1/PCWG3 criteria.
Time frame: From first dose of docetaxel/carboplatin to the date of first objective evidence of radiographic progression (soft tissue or bone lesion) or death due to any cause, whichever occurs first, assessed up to 3.75 years.
Overall Response Rate (ORR) of Measurable Disease (PCWG3) (Complete Response or Partial Response) Assessed by Modified RECIST Version 1.1 Criteria
Overall response rate of measurable disease (PCWG3): radiologic ORR (CR or PR per modified RECIST Version 1.1 criteria and no bone progression per PCWG3 prior to a CR or PR) by investigator assessment in patients with measurable visceral and/or nodal disease at baseline per IRR (Cohort A). An analysis of radiologic ORR by the investigator will also be conducted as supportive to the primary endpoint.
Time frame: Up to 3.75 years
Prostate-specific Antigen (PSA) Nadir After Induction
Rate of confirmed PSA decrease from baseline, assessed by a local laboratory (PSA50 and PSA90). Number of patients achieving a PSA decline from baseline of ≥50% (PSA50) or ≥90% (PSA90). The change in PSA was calculated relative to the PSA level at the start of cycle 1.
Time frame: Up to 13 weeks
PSA Nadir After Maintenance
Rate of confirmed PSA decrease from baseline, assessed by a local laboratory (PSA50 and PSA90) using postchemotherapy PSA as the baseline. The most recent PSA level before PARPi initiation was used as the baseline PSA. Number of patients achieving a PSA decline from baseline of ≥50% (PSA50) or ≥90% (PSA90).
Time frame: Up to 3.5 years
PSA Response Duration
PSA-response duration: duration of confirmed response is defined as the time from the date that a response (PSA decrease ≥ 50%) is first reported to the time that PSA progression is first documented.
Time frame: From the date that a response (PSA decrease >= 50%) is first reported to the time that PSA progression is first documented, assessed up to 3.75 years
Time to PSA Progression (PCWG3)
Time to PSA progression is defined as the time from first dose of docetaxel/carboplatin to the date that a ≥ 25% increase and absolute increase of ≥ 2 ng/mL above the nadir (or baseline value for patients who did not have a decline in PSA) in PSA was measured. The increase must be confirmed by a second consecutive assessment conducted at least 3 weeks later.
Time frame: From first dose of docetaxel/carboplatin to the date that a >= 25% increase and absolute increase of >= 2 ng/mL above the nadir (or baseline value for patients who did not have a decline in PSA) in PSA was measured, assessed up to 3.75 years.
| Milestone | Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate) |
|---|---|
| Started | 18 |
| Completed | 16 |
| Not completed | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Death | 1 |
| Milestone | Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate) |
|---|---|
| Started | 16 |
| Completed | 0 |
| Not completed | 16 |
| Withdrew: Adverse event | 2 |
| Withdrew: Death | 1 |
| Withdrew: Disease progression | 12 |
| Withdrew: Withdrawal by subject | 1 |
Radiologic progression free survival (rPFS) is defined as the time from first dose of docetaxel/carboplatin to the date of first objective evidence of radiographic progression (soft tissue or bone lesion) or death due to any cause, whichever occurs first. Radiographic disease progression includes confirmed bone disease progression and soft tissue disease progression adjudicated by investigator assessment using the RECIST 1.1/PCWG3 criteria.
| Months | Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate) |
|---|---|
| Radiographic Progression Free Survival Assessed by Assessment Using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1/Prostate Cancer Working Group 3 (PCWG3) Criteria | 8.1 (6.5 to 31.2) |
Overall response rate of measurable disease (PCWG3): radiologic ORR (CR or PR per modified RECIST Version 1.1 criteria and no bone progression per PCWG3 prior to a CR or PR) by investigator assessment in patients with measurable visceral and/or nodal disease at baseline per IRR (Cohort A). An analysis of radiologic ORR by the investigator will also be conducted as supportive to the primary endpoint.
| Participants | Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate) |
|---|---|
| Partial Response | 3 |
| Stable Disease | 9 |
| Progressive Disease | 2 |
Rate of confirmed PSA decrease from baseline, assessed by a local laboratory (PSA50 and PSA90). Number of patients achieving a PSA decline from baseline of ≥50% (PSA50) or ≥90% (PSA90). The change in PSA was calculated relative to the PSA level at the start of cycle 1.
| Participants | Induction (Docetaxel and Carboplatin) |
|---|---|
| PSA decline from baseline of ≥50% | 7 |
| PSA decline from baseline of ≥90% | 1 |
| PSA decline from baseline of <50% | 4 |
| PSA Increase | 6 |
Rate of confirmed PSA decrease from baseline, assessed by a local laboratory (PSA50 and PSA90) using postchemotherapy PSA as the baseline. The most recent PSA level before PARPi initiation was used as the baseline PSA. Number of patients achieving a PSA decline from baseline of ≥50% (PSA50) or ≥90% (PSA90).
| Participants | Maintenance (Rucaparib Camsylate) |
|---|---|
| PSA decline from postchemotherapy of ≥50% | 4 |
| PSA decline from postchemotherapy of ≥90% | 4 |
| PSA decline from postchemotherapy of <50% | 1 |
| PSA Increase | 7 |
PSA-response duration: duration of confirmed response is defined as the time from the date that a response (PSA decrease ≥ 50%) is first reported to the time that PSA progression is first documented.
| Months | Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate) |
|---|---|
| Subject 1 | 12.43 |
| Subject 2 | 0.67 |
| Subject 3 | 36.86 |
| Subject 4 | 24.03 |
| Subject 5 | 12 |
| Subject 6 | 4.86 |
| Subject 7 | 4.6 |
| Subject 8 | 19.86 |
| Subject 9 | 4.56 |
| Subject 10 | 8.23 |
Time to PSA progression is defined as the time from first dose of docetaxel/carboplatin to the date that a ≥ 25% increase and absolute increase of ≥ 2 ng/mL above the nadir (or baseline value for patients who did not have a decline in PSA) in PSA was measured. The increase must be confirmed by a second consecutive assessment conducted at least 3 weeks later.
| Months | Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate) |
|---|---|
| Time to PSA Progression (PCWG3) | 5.2 (3.2 to 20.9) |
Collected over Only treatment-emergent adverse events (TEAEs) were collected: TEAEs are defined as AEs with onset date on or after the date of first dose of study drug until the date of the last study drug dose plus 28 days (up to 3.75 years total).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Induction Phase (Docetaxel and Carboplatin) | 1/18 (5.6%) | 2/18 (11.1%) | 18/18 (100%) |
| Maintenance Phase (Rucaparib Camsylate) | 1/16 (6.3%) | 1/16 (6.3%) | 16/16 (100%) |
| Event | Induction Phase (Docetaxel and Carboplatin) | Maintenance Phase (Rucaparib Camsylate) |
|---|---|---|
| Intractable VomitingGastrointestinal disorders | 0/18 | 1/16 |
| Cerebral Venous Sinus ThrombosisNervous system disorders | 0/18 | 1/16 |
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 0/18 | 1/16 |
| Skin ulceration, right footSkin and subcutaneous tissue disorders | 0/18 | 1/16 |
| Starvation KetoacidosisMetabolism and nutrition disorders | 1/18 | 0/16 |
| Acute KetoacidosisMetabolism and nutrition disorders | 1/18 | 0/16 |
| Event | Induction Phase (Docetaxel and Carboplatin) | Maintenance Phase (Rucaparib Camsylate) |
|---|---|---|
| FatigueGeneral disorders | 15/18 | 12/16 |
| AnemiaBlood and lymphatic system disorders | 11/18 | 6/16 |
| NauseaGastrointestinal disorders | 9/18 | 6/16 |
| ConstipationGastrointestinal disorders | 8/18 | 6/16 |
| DiarrheaGastrointestinal disorders | 8/18 | 3/16 |
| AnorexiaMetabolism and nutrition disorders | 7/18 | 5/16 |
| Weight lossInvestigations | 2/18 | 5/16 |
| Elevated creatinineInvestigations | 1/18 | 5/16 |
| HypomagnesemiaMetabolism and nutrition disorders | 5/18 | 3/16 |
| ThrombocytopeniaInvestigations | 5/18 | 4/16 |
| Age, Categorical(Participants) | Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate) |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 6 |
| >=65 years | 12 |
| Sex: Female, Male(Participants) | Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate) |
|---|---|
| Female | 0 |
| Male | 18 |
| Ethnicity (NIH/OMB)(Participants) | Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate) |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 16 |
| Unknown or Not Reported | 2 |
| Race (NIH/OMB)(Participants) | Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 15 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| PSA at Diagnosis(ng/mL) | Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate) |
|---|---|
| Participant 1 | 16 |
| Participant 2 | 5 |
| Participant 3 | 42 |
| Participant 4 | 129 |
| Participant 5 | 156 |
| Participant 6 | 540 |
| Participant 7 | 6 |
| Participant 8 | 588 |
| Participant 9 | 132 |
| Participant 10 | 7 |
| Participant 11 | 25 |
| Participant 12 | 36 |
| Participant 13 | 17 |
| Participant 14 | 13 |
| Participant 15 | 2040 |
| Participant 16 | 35 |
| Participant 17 | 4374 |
| Participant 18 | 1101 |
| Primary treatment (radical prostatectomy or radiation)(Participants) | Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate) |
|---|---|
| Prostatectomy | 5 |
| Radiation | 1 |
| Neither | 12 |
| Prior therapies for castration resistant prostate cancer(Participants) | Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate) |
|---|---|
| 1 Therapy | 4 |
| 2 Therapies | 8 |
| 3 or more Therapies | 6 |
| BRCA/ATM/other HR gene mutation status(participants) | Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate) |
|---|---|
| ATM | 7 |
| BRCA1 | 3 |
| BRCA2 | 8 |
| PALB2 | 1 |
| FANCA | 1 |
| CHD1 + SPOP | 1 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2018 to primary completion in Jun 2025, 81 months.
Results were first posted in Aug 2026, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Carboplatin · Docetaxel · Rucaparib